NAVIGATOR data show half of patients with severe, uncontrolled asthma improved with tezepelumab therapy
Nearly half of patients at high risk for lung cancer delayed screening follow-up
17 May 2022Near-infrared light fluorescence in mice optimizes tumor removal, reduces cancer recurrence
17 May 2022NAVIGATOR data show half of patients with severe, uncontrolled asthma improved with tezepelumab therapy
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab than placebo, according to research published at the ATS 2022 international conference. The study showed that nearly half of those enrolled achieved complete response to treatment across measures of exacerbation reduction, asthma control, lung function, and clinician assessment.
